ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to today outline the key abstract information presented on Wednesday 14 November at the 2012 Annual American College of Rheumatology (“ACR”) Meeting which was held this week. The ACR Annual Scientific Meeting is the premier worldwide scientific meeting devoted…

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to confirm that it will be presenting at the 2012 Annual American College of Rheumatology (“ACR”) Meeting  which is being held between 11 – 14 of November. ImmuPharma will be presenting on Wednesday 14 November 2012. The ACR…

ImmuPharma plc (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist drug discovery and development company, is pleased to announce that its cancer programme IPP-204106 has begun further clinical trials with the next generation of “polyplexed Nucant”. The first patients have started dosing in this new Phase I/ II clinical trial. This “polyplexed Nucant”…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to confirm that it will be presenting at the Rodman and Renshaw Annual Global Investment Conference on Tuesday 11 September 2012 at the Waldorf Astoria in New York City. Tracy Weimar, Vice President, Operations and Finance will present an…

ImmuPharma PLC (LSE: IMM) (“ImmuPharma” or the “Company”), the specialist discovery and development pharmaceutical company, has been voted “Best Medical Research and Development Company, Europe” at The New Economy Pharmaceutical & Healthcare Awards 2012. This is the second time ImmuPharma has won this prestigious award, the first being in 2010 when voted “Best Drug Development…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug development company, is pleased to announce the appointment of Cenkos Securities plc, as Joint Broker to the Company, with immediate effect. Commenting on the appointment of Cenkos, Dimitri Dimitriou, ImmuPharma’s Chief Executive Officer said: “We are delighted to be working more closely with Cenkos. The Cenkos team brings…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2011.

ImmuPharma PLC (AIM: IMM), the specialist drug development company, is pleased to announce that it has appointed Lisa Baderoon as Head of Investor Relations.